Iván Plaza-Menacho

Abstract Gene fusion products involving protein kinases are known drivers in human cancers and actionable targets for personalized therapy, yet the structural and molecular determinants that control their function are largely unexplored. Here we show that a CCDC6-RET fusion protein, a driver and therapeutic target in lung and thyroid cancers, is a highly active dimeric kinase.

Accepted manuscript, PDF only. Full online edition to follow. Accepted Manuscript June 21, 2024 Share this article Cite this article Discovery of runs-of-homozygosity diplotype clusters and their associations with diseases in UK Biobank eLife 13:e81698. https://doi.org/10.7554/eLife.81698 Data availability This research has been conducted using the UK Biobank Resource under Application Number 24247.The source code is available at https://github.com/ZhiGroup/ROH-DICE.

For decades reactive oxygen species were considered to be the by-products of cell damage. However, more recently these unstable molecules have been shown to play a role in cell signaling as secondary messengers that transfer electrons between proteins. This exchange of electrons, known as a redox modification, typically takes place on a specific set of amino acids within the protein.